In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Innovation Center Copenhagen AS

Division of Roche

Latest From Roche Innovation Center Copenhagen AS

Noxxon Pharma makes addition to supervisory board

Berlin, Germany and Boston, USA-based Noxxon Pharma has named Don deBethizy to the company's supervisory board. In his last position as president and chief executive officer of Santaris Pharma, Mr deBethizy initiated and managed the successful acquisition of the company by Roche. Previously, he was executive chair of Danish bio-venture firm, Contera Pharma. Noxxon is developing a new class of proprietary therapeutics called Spiegelmers, which are chemically synthesized L-stereoisomer oligonucleotide aptamers, a non-immunogenic alternative to antibodies.

Germany Companies

Canadian newcomer Liphorus sets sights on oral PCSK inhibitors

A new company, Liphorus Pharmaceuticals, has been spun out of Canada's IRCM (Institut de recherches cliniques de Montréal) to develop small-molecule drugs that inhibit PCSK9 for the treatment of high cholesterol.

Canada Clinical Trials

Forbion’s New Fund

Dutch venture capital firm, Forbion Capital Partners, has launched a new €92 milion ($116 million) life science fund to invest in 12 to 15 new companies. This is first close for the new fund called Forbion Capital Fund III, en route to a target of €150 to €200 million.

Medical Device

Deals In Depth: August 2014

In a transaction worth $650 million in pre-commercial payments, Daiichi Sankyo got exclusive US rights to Charleston Labs’ hydrocodone combos for pain; Roche acquired two of its partners, InterMune and Santaris. Both biopharma and device financing were down in August compared with July.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Ophthalmic
  • Alias(es)
  • Pantheco AS
  • Cureon AS
  • Santaris Pharma AS
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Denmark
  • Parent & Subsidiaries
  • Roche
  • Senior Management
  • J. Donald deBethizy, PhD, Pres. & CEO
    Henrik Stage, CFO & EVP, Corp. Dev.
    Henrik Oerum, PhD, CSO & VP, Bus. Dev.
  • Contact Info
  • Roche Innovation Center Copenhagen AS
    Phone: (45) 45179800
    Fremtidsvej 3
    Horsholm, DK-2970